Andrew Scharenberg, MD

Andy is the founder and chief executive officer of Umoja Biopharma and an executive partner/entrepreneur at MPM Capital. Previously he was the chief scientific officer at Casebia. Before joining Casebia, Andy was an attending physician at Seattle Children’s Hospital and principal investigator in the Center for Immunity and Immunotherapies at Seattle Children’s Research Institute. In addition, he served as a co-director of the Program for Cell and Gene Therapy at Seattle Children’s Hospital, a professor in the Department of Pediatrics, and an adjunct professor in the Department of Immunology at the University of Washington School of Medicine. He was also a member of the Transplantation Biology Consortium Program at Fred Hutchinson Cancer Center. As the chief scientific officer at Cellectis, Andy helped implement a gene-editing partnership with Pfizer. Andy earned his Bachelor of Science in biochemistry from Indiana University and his medical degree from the University of North Carolina School of Medicine.